Details for Patent: 10,730,876

Which drugs does patent 10,730,876 protect, and when does it expire?

Patent 10,730,876 protects TURALIO and is included in one NDA.

This patent has fifty-four patent family members in twenty-eight countries.

Summary for Patent: 10,730,876

Patent landscape, scope, and claims:

Title:	Synthesis of a compound that modulates kinases
Abstract:	The present disclosure provides processes for the preparation of a compound of formula I: ##STR00001## or a salt thereof, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
Inventor(s):	Ibrahim; Prabha N. (Mountain View, CA), Jin; Masayoshi (Tokyo, JP), Matsuura; Shinji (Tokyo, JP)
Assignee:	Plexxikon Inc. (Berkeley, CA) Daiichi Sankyo Company, Limited (Tokyo, JP)
Application Number:	16/510,617
Patent Claim Types: see list of patent claims	Compound; Process;

Drugs Protected by US Patent 10,730,876

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-002	Oct 14, 2022		RX	Yes	No	10,730,876			Y
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		DISCN	Yes	No	10,730,876			Y

International Family Members for US Patent 10,730,876

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016258027
Brazil	112017023490
Brazil	112017023540
Canada	2984899
Canada	2984910
China	107531706